BioCentury
ARTICLE | Emerging Company Profile

IkerChem: Binding site rationale

December 14, 2009 8:00 AM UTC

IkerChem S.L. is using computational drug design to develop molecules that cover the entire active binding site of their targets. The company believes the approach can yield a larger number of more potent hits in early discovery research than is possible with ligand-based screening methods, producing clinical candidates faster.

An HDAC inhibitor discovered using the approach is slated to enter the clinic to treat cancer in 2010...